[go: up one dir, main page]

UY30462A1 - Composicion farmacéuticas que contiene un acido tetrahidrofolico. - Google Patents

Composicion farmacéuticas que contiene un acido tetrahidrofolico.

Info

Publication number
UY30462A1
UY30462A1 UY30462A UY30462A UY30462A1 UY 30462 A1 UY30462 A1 UY 30462A1 UY 30462 A UY30462 A UY 30462A UY 30462 A UY30462 A UY 30462A UY 30462 A1 UY30462 A1 UY 30462A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
composition containing
estrogen
progestogen
tetrahydrofolic acid
Prior art date
Application number
UY30462A
Other languages
English (en)
Inventor
Kristina King
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36763829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30462(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY30462A1 publication Critical patent/UY30462A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Composiciones farmacéuticas solidas, en particular anticonceptivos orales, que comprenden un progestágeno, tal como drospirenona; un estrogeno, tal como etinilestradiol; un ácido tetrahidrofolico o una de sus sales adecuadas para uso farmacéutico , tal como 5-metil-(6S) -tetrahidrofolato de calcio; y por lo menos un excipiente o vehículo adecuado para el uso farmacéutico. Las composiciones de la invencion proporcionan buena estabilidad del ácido tetrahidrofolico durante el almacenamiento asegurado no obstante una liberacion rápida y confiable del estrogeno y del progestágeno presentes en la composicion.
UY30462A 2006-07-06 2007-07-04 Composicion farmacéuticas que contiene un acido tetrahidrofolico. UY30462A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06014002 2006-07-06

Publications (1)

Publication Number Publication Date
UY30462A1 true UY30462A1 (es) 2008-02-29

Family

ID=36763829

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30462A UY30462A1 (es) 2006-07-06 2007-07-04 Composicion farmacéuticas que contiene un acido tetrahidrofolico.

Country Status (31)

Country Link
EP (2) EP2040683B2 (es)
JP (1) JP2009542591A (es)
KR (2) KR20090033889A (es)
CN (3) CN101489563A (es)
AR (2) AR061958A1 (es)
AU (1) AU2007271449B2 (es)
BR (1) BRPI0713565B8 (es)
CA (2) CA2656131C (es)
CL (1) CL2007001962A1 (es)
CO (1) CO6150125A2 (es)
CR (1) CR10549A (es)
CU (1) CU20090004A7 (es)
EC (1) ECSP099030A (es)
ES (1) ES2626838T5 (es)
GT (1) GT200900001A (es)
IL (3) IL196027A0 (es)
MA (1) MA30598B1 (es)
MX (1) MX2009000079A (es)
MY (1) MY169516A (es)
NO (1) NO347567B1 (es)
NZ (1) NZ573766A (es)
PE (3) PE20120375A1 (es)
PH (1) PH12012501774B1 (es)
RU (2) RU2479306C2 (es)
SG (1) SG188869A1 (es)
TN (1) TNSN08543A1 (es)
TW (2) TWI508730B (es)
UA (2) UA100228C2 (es)
UY (1) UY30462A1 (es)
WO (1) WO2008003432A1 (es)
ZA (4) ZA200900868B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
BR112012026115B1 (pt) 2010-04-15 2019-12-24 Bayer Ip Gmbh forma de dosagem oral sólida, seu uso, e unidade de acondicionamento
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
CN102516247A (zh) * 2010-12-15 2012-06-27 连云港金康医药科技有限公司 A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
EP2878600B1 (en) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
CN107812195B (zh) * 2014-09-04 2021-04-20 连云港金康和信药业有限公司 (6s)‐5‐甲基‐四氢叶酸钙盐的稳定药物组合物
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
JP6863547B2 (ja) 2015-06-18 2021-04-21 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
MA44206B1 (fr) 2015-06-18 2021-04-30 Estetra Sprl Comprimé orodispersible comprenant estetrol
CN105030779A (zh) * 2015-07-21 2015-11-11 福格森(武汉)生物科技股份有限公司 一种(6s)-5-甲基四氢叶酸钙口服营养补充剂及其制备方法
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
CN107446458A (zh) * 2017-08-04 2017-12-08 合众(佛山)化工有限公司 一种高耐水性的丙烯酸改性聚氨酯杂化树脂水性涂料
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
CN110237046B (zh) * 2019-03-29 2021-07-30 福格森(武汉)生物科技股份有限公司 一种l-5-甲基四氢叶酸微囊的制备方法
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
IT202100008834A1 (it) * 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
CN114569567B (zh) * 2021-12-20 2023-03-14 南通联亚药业股份有限公司 一种稳定的双醋炔诺酮炔雌醇复方片及其制备方法
CN115813937B (zh) * 2022-12-01 2025-04-11 南通联亚药业股份有限公司 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法
WO2025132557A1 (en) * 2023-12-20 2025-06-26 Lesaffre Et Compagnie Solid formulations of tetrahydrofolates
CN117771389A (zh) * 2023-12-28 2024-03-29 浙江圣达生物药业股份有限公司 L-5-甲基四氢叶酸钙-γ-环糊精包合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
FR2676927B1 (fr) * 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
KR100384264B1 (ko) * 1994-09-22 2003-08-30 악조 노벨 엔.브이. 습식과립화에의한 투여단위의제조방법
RU2073529C1 (ru) * 1995-05-16 1997-02-20 Центральный научно-исследовательский рентгенорадиологический институт Композиция для эмболизации кровеносных сосудов
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CN1240387C (zh) * 1998-04-17 2006-02-08 奥索一麦克尼尔药品公司 含有叶酸的药用组合物及其用途和给药系统
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
CA2382426C (en) * 1999-08-31 2006-02-28 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
RS50262B2 (sr) * 1999-08-31 2018-10-31 Bayer Pharma AG Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva
ATE442147T1 (de) * 2000-01-18 2009-09-15 Bayer Schering Pharma Ag Pharmazeutische zubereitung enthaltend drospirenon
US6550482B1 (en) * 2000-04-21 2003-04-22 Vascular Control Systems, Inc. Methods for non-permanent occlusion of a uterine artery
US6864774B2 (en) 2000-10-19 2005-03-08 Matsushita Electric Industrial Co., Ltd. Inductance component and method of manufacturing the same
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US6537569B2 (en) * 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
RS50909B (sr) * 2002-02-21 2010-08-31 Bayer Schering Pharma Aktiengesellschaft Farmaceutske kompozicije koje se sastoje od jednog ili više steroida, jedne ili više tetrahidrofolatne komponente i vitamina b12
US20060069168A1 (en) * 2002-10-29 2006-03-30 Norikazu Tabata Vascular embolization material
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
MX2009000256A (es) * 2006-07-06 2009-02-18 Bayer Schering Pharma Ag Preparaciones farmaceuticas para la anticoncepcion y para prevenir el riesgo de malformaciones congenitas.
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
RU62008U1 (ru) * 2006-10-13 2007-03-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
RU61120U1 (ru) * 2006-10-13 2007-02-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block

Also Published As

Publication number Publication date
NO20090578A (no) 2009-03-09
MY169516A (en) 2019-04-22
EP2422774A1 (en) 2012-02-29
RU2624236C2 (ru) 2017-07-03
UA105078C2 (uk) 2014-04-10
CN101489563A (zh) 2009-07-22
CR10549A (es) 2009-01-27
ECSP099030A (es) 2009-02-27
TW200812593A (en) 2008-03-16
IL245355B (en) 2019-05-30
BRPI0713565B1 (pt) 2021-02-02
NO347567B1 (no) 2024-01-15
CN101484143A (zh) 2009-07-15
CA2856344A1 (en) 2008-01-10
CN102813663B (zh) 2019-03-22
CL2007001962A1 (es) 2008-01-04
ZA200900868B (en) 2021-05-26
MX2009000079A (es) 2009-01-23
SG188869A1 (en) 2013-04-30
TNSN08543A1 (en) 2010-04-14
CN101484143B (zh) 2012-07-04
ES2626838T3 (es) 2017-07-26
BRPI0713565B8 (pt) 2021-05-25
GT200900001A (es) 2009-12-08
AR106561A2 (es) 2018-01-24
CA2856344C (en) 2017-02-28
HK1131917A1 (en) 2010-02-12
CU20090004A7 (es) 2011-07-11
WO2008003432A1 (en) 2008-01-10
PE20150287A1 (es) 2015-03-15
EP2040683B2 (en) 2023-08-16
KR20130042638A (ko) 2013-04-26
EP2040683A1 (en) 2009-04-01
MA30598B1 (fr) 2009-07-01
KR20090033889A (ko) 2009-04-06
PH12012501774A1 (en) 2015-09-21
TW201538161A (zh) 2015-10-16
ZA201808084B (en) 2021-06-30
CA2656131A1 (en) 2008-01-10
AU2007271449A1 (en) 2008-01-10
UA100228C2 (uk) 2012-12-10
BRPI0713565A2 (pt) 2012-03-20
CN102813663A (zh) 2012-12-12
JP2009542591A (ja) 2009-12-03
IL245355A0 (en) 2016-06-30
AU2007271449B2 (en) 2013-07-11
PE20120375A1 (es) 2012-05-23
CA2656131C (en) 2015-10-13
RU2009103649A (ru) 2010-08-20
NO20090578L (no) 2009-03-09
PH12012501774B1 (en) 2015-09-21
PE20080273A1 (es) 2008-05-16
AR061958A1 (es) 2008-08-10
ZA201808083B (en) 2021-06-30
ES2626838T5 (es) 2024-03-14
CU23902B1 (es) 2013-06-28
IL196027A0 (en) 2009-09-01
TWI508730B (zh) 2015-11-21
ZA201501673B (en) 2016-02-24
CO6150125A2 (es) 2010-04-20
IL224484A (en) 2016-05-31
RU2012133154A (ru) 2014-02-10
EP2422774B1 (en) 2015-08-12
NZ573766A (en) 2011-05-27
EP2040683B1 (en) 2017-03-01
RU2479306C2 (ru) 2013-04-20

Similar Documents

Publication Publication Date Title
UY30462A1 (es) Composicion farmacéuticas que contiene un acido tetrahidrofolico.
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CL2009002187A1 (es) Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).
PE20061091A1 (es) FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRANDINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
CR9786A (es) Compuestos de bencimidazol-tiofeno
CU23616B7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
AR055070A1 (es) Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso
PE20070208A1 (es) Anticoncepcion oral con trimegestona
ECSP066715A (es)
CU20060038A7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
ECSP066999A (es) Envase farmacéutico para anticoncepción hormonal de régimen extendido flexible
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
ECSP077262A (es) Composicion antihistaminica
ECSP10010578A (es) Composicion farmaceutica 271
HN2009000012A (es) Composicion farmaceutica que contiene un acido tetrahidrofolico
AR052365A1 (es) Derivados antihelminticos de imidazol-tiazol
SG144065A1 (en) Oral contraceptive spray
DOP2007000117A (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
CU23727B7 (es) Composición farmacéutica que contiene drospirenona, etinilestradiol y la sal de calcio del ácido 5-metil-(6s)-tetrahidrofólico
BRPI0500420A (pt) composição estável para substáncia farmacologicamente ativa

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20201222